What the finding on your MRI actually is

Being told you have a 'focal chondral lesion' on your hip scan can feel alarming — yet the phrase has a precise meaning that is worth unpacking before anything else.

Focal means the damage is localised to one area of the joint surface rather than spread across the whole hip. This is a meaningful distinction from hip osteoarthritis, where cartilage thins diffusely over months or years. A focal defect is contained, which is exactly what makes it a candidate for targeted repair rather than joint replacement.

Chondral means the injury affects the cartilage layer itself. An osteochondral lesion goes deeper, involving the bone immediately beneath — a different repair target with a different clinical plan.

The two main sites are the acetabulum (the socket) and the femoral head (the ball). Acetabular lesions are far more common and better studied. Most arise from cam-type femoroacetabular impingement, in which a non-spherical femoral head repeatedly shears the anterosuperior acetabular cartilage and chondrolabral junction during hip flexion.

Finally, a MRI finding and a source of pain are not the same thing. Cartilage changes can appear on imaging in people without significant symptoms, and groin pain can exist without obvious structural damage. A specialist uses the scan alongside your history and physical examination to judge clinical relevance.

Why hip cartilage cannot repair itself

Unlike bone or muscle, hip cartilage has no blood supply. It draws nutrients from synovial fluid rather than capillaries, which means that when a defect forms, no repair cells can reach the site — the damage is permanent without intervention.

The practical consequence is a self-reinforcing deterioration cycle. Shear stress concentrates at the defect rim rather than distributing evenly across the joint surface, fragmenting the edge and progressively widening the lesion. As the defect deepens, subchondral bone is exposed, producing marrow oedema and cyst formation. The accepted end-point of this cycle, left unchecked, is diffuse hip osteoarthritis and eventual total hip replacement.

Precise timelines for that progression are inferred from structural imaging studies rather than measured in long-term controlled hip cohorts — the direction of travel is well established; how quickly it proceeds in any individual remains uncertain.

This is the conceptual foundation of joint preservation: act while the defect is still focal and contained, before the mechanical cycle widens it beyond the reach of repair. That does not mean emergency surgery — it means specialist assessment early enough to keep options open.

What your MRI can and cannot tell the surgeon

The scan report is one input, not the final word. A 3.0T MRI — or an MR arthrogram with injected contrast — is the accepted standard for assessing hip cartilage, but its precision has well-defined limits that are worth understanding before your specialist appointment.

A 2025 study of 233 patients with femoroacetabular impingement measured scan accuracy against arthroscopic findings, which remain the diagnostic reference point. For detecting acetabular chondral delamination, 3.0T MRI achieved sensitivity of 83.7% and specificity of 82%. The most reassuring figure is the negative predictive value of 89.1%: when the scan shows nothing significant, it is usually correct. The difficulty runs the other way — when a defect is present, MRI consistently underestimates its severity compared with what the surgeon sees directly. A 'mild' finding on imaging may look more serious at arthroscopy.

Alpha angle, measured from the same scan, adds useful risk context. Each one-degree increase in alpha angle carries an odds ratio of 1.04 for higher-grade cartilage damage; men show roughly twice the risk of severe damage compared with women at equivalent alpha angles — information that helps the surgeon weigh urgency before operating.

In specialist settings, delayed gadolinium-enhanced MRI (dGEMRIC) can assess the biochemical composition of cartilage before obvious structural failure — relevant for pre-surgical joint-preservation planning, though not part of routine NHS imaging.

Definitive grading happens only when the joint is visualised directly. Outerbridge grading (grades I–IV) assigned at arthroscopy is what actually drives treatment decisions. The MRI is an essential map — but ground truth belongs to the surgeon looking inside the joint.

How the joint-preservation decision pathway works

Clinical decision-making for a focal hip chondral lesion follows four stages — and moving through them in sequence, rather than jumping ahead, is itself a form of joint protection.

Stage one: specialist diagnosis. A GP referral is the appropriate trigger when groin or anterior hip pain has not settled after six to eight weeks of activity modification, or when a scan shows a focal lesion that needs interpreting alongside symptoms and movement mechanics. A scan finding alone is not a treatment indication.

Stage two: conservative management. Load modification, targeted physiotherapy, and analgesic support are the correct first response for most patients without acute structural failure. Joint preservation begins with not overloading a hip that has already lost some surface integrity. Many patients stabilise here and do not progress further.

Stage three: biologic or injection-based support. When conservative care reaches a plateau, supplementary treatments can reduce intra-articular inflammation, support the joint environment, or — in the case of regenerative scaffolds — aim to address the defect directly.

Stage four: surgical or restorative intervention. The need for this stage is guided primarily by lesion size and grade. Defects below 2 cm² are managed differently from those in the 2–4 cm² range; morphology also matters — delamination, partial-thickness fibrillation, and full-thickness bone exposure each point towards different approaches. Grade III–IV lesions, involving deep fibrillation or exposed subchondral bone, consistently carry a higher risk of eventual total hip replacement regardless of the technique used. That is a clinical reality, not an inevitability, but it represents the honest upper boundary of what focal joint preservation can achieve.

The pathway is a sequence, not a menu, and most patients do not reach stage four.

Treatment options across the pathway

Lesion size, depth, and morphology determine which option is appropriate — there is no single procedure that suits every defect.

Small or low-grade lesions (fibrillation, <2 cm²). Debridement or chondroplasty smooths the damaged surface and can reduce mechanical irritation, but evidence does not show a durable advantage over the natural history of small defects. Standalone microfracture has largely fallen out of favour for the same size category: outcomes are comparable to debridement alone, and it carries real risks of subchondral fracture and intralesional osteophyte — complications that can limit future options.

Augmented microfracture (e.g., BioCartilage allograft + PRP). Adding micronised allograft cartilage and autologous conditioned PRP to the microfracture bed improves the biological environment. In a series of 91 patients, 89.3% reached the minimal clinically important difference and 82.5% crossed the patient acceptable symptom state at two years — a meaningful improvement over standalone microfracture. The caveat is important: 10.9% still converted to total hip replacement within the same follow-up window.

Delamination lesions with an intact flap. Where the cartilage has separated but the flap remains structurally viable, chondral nail fixation outperforms debridement. In a propensity-matched study, 75.9% of the fixation group met the pain PASS threshold versus 48.3% in the debridement group (p = .030), with no THA conversions at two years.

Medium defects (2–4 cm²). AMIC — autologous membrane-induced chondrogenesis — produced a mean mHHS improvement of +39 points at five years in a 201-patient series, with peak gains at year three.

Larger contained defects (≥3 cm²). MACI (matrix-induced autologous chondrocyte implantation) outperforms microfracture at both two- and five-year follow-up in active patients, supported by SUMMIT trial data.

Injectable collagen scaffold (ChondroFiller injection). For patients seeking an outpatient, ultrasound-guided route, ChondroFiller injection places an acellular collagen scaffold into the defect without disturbing the subchondral bone layer. Published hip-specific data remain at early case-report level — one documented case of a contained femoral head defect achieved full pain resolution — so direct numerical comparison with the surgical series above is not yet possible. Its practical distinction is the delivery route: a single-stage, image-guided outpatient procedure rather than an operating theatre.

No randomised controlled trial has compared these techniques head-to-head with long follow-up. All outcome figures cited above come from single-arm or matched observational series, and results should be interpreted accordingly.

Getting assessed at the right time

Specialist assessment is the bridge between receiving a scan report and knowing what it means for daily life and long-term joint health. Where existing imaging is plain MRI rather than arthrographic, the specialist may request an MR arthrogram before confirming a treatment pathway, since severity tends to be underestimated on plain sequences alone.

The consultation brings together a structured hip history, clinical examination — range of movement, impingement provocation testing, and a check for pain sources outside the joint — and a review of imaging already to hand. The outcome is a decision about which pathway stage applies: continued conservative management, biologic or injection support, or further discussion of a restorative option.

For patients pursuing an outpatient regenerative route, ChondroFiller injection — ultrasound-guided and single-stage — is available through Professor Paul Y. F. Lee at the London Cartilage Clinic on Harley Street; assessment can be arranged via londoncartilage.com.

For anyone who proceeds to a restorative procedure, the MERCH score provides a validated MRI framework for tracking repair quality — seven domains covering fill volume, surface integration, and subchondral changes — assessed at twelve months or later on a 3.0T scanner. It brings the clinical conversation full circle: the same imaging modality that identified the defect becomes the tool for measuring whether repair is on track.

1. [1] Editorial Commentary: Hip Chondral Defect Treatment Requires Cells, Signal, and Scaffold. (2022). https://doi.org/10.1016/j.arthro.2022.06.007 https://doi.org/10.1016/j.arthro.2022.06.007
2. [2] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
3. [3] Accuracy of MRI in the Diagnosis of Acetabular Chondral Delamination in Femoroacetabular Impingement. (2025). https://doi.org/10.1093/jhps/hnaf069.115 https://doi.org/10.1093/jhps/hnaf069.115
4. [4] Alpha angle values predict the severity of hip chondral damage in cam-type FAI: systematic review and meta-analysis. (2024). https://doi.org/10.1016/j.arthro.2024.08.032 https://doi.org/10.1016/j.arthro.2024.08.032
5. [5] Arthroscopic Treatment of Hip Chondral Defect With Microfracture and PRP-Infused Micronized Cartilage Allograft Augmentation. (2018). https://doi.org/10.1016/j.eats.2017.10.005 https://doi.org/10.1016/j.eats.2017.10.005
6. [6] Autologous Membrane Induced Chondrogenesis (AMIC) for the treatment of acetabular chondral defect. (2016). https://doi.org/10.11138/mltj/2016.6.3.367 https://doi.org/10.11138/mltj/2016.6.3.367
7. [7] Sustained benefit of autologous matrix-induced chondrogenesis for hip cartilage repair in a recreational athletic population. (2019). https://doi.org/10.1007/s00167-019-05801-y https://doi.org/10.1007/s00167-019-05801-y
8. [8] Defining hip cartilage repair: MERCH score (Magnetic Resonance Evaluation of the Repair of Cartilage in the Hip). (2023). https://doi.org/10.1186/s40634-023-00676-y https://doi.org/10.1186/s40634-023-00676-y
9. [9] Rates of Achieving Meaningful Outcomes 2-Year After Microfracture Augmented with Allograft Cartilage and PRP For Hip Chondral Defects. (2025). https://doi.org/10.1093/jhps/hnaf011.072 https://doi.org/10.1093/jhps/hnaf011.072